45 Advanced Solid Tumors Clinical Trials in Dallas, PA (2026)

Q: How do I join a clinical trial in Dallas?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Dallas research site will contact you.

Recruiting Advanced Solid Tumors Studies in Dallas

NCT00992303Recruiting

Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants

RATIONALE: Collecting and storing samples of tissue from patients with cancer to test in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting tissue s...

Dallas, PA10,000 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT05279300Recruiting

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 used as a single agent and in combination with systemic therapies in patients with adva...

Dallas, PA480 participantsCStone Pharmaceuticals

View Study Details

NCT05007782Recruiting

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

This is a first-in-human (FIH) study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of denikitug (also known as GS...

Dallas, PA416 participantsGilead Sciences

View Study Details

NCT06619587Recruiting

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single ag...

Dallas, PA410 participantsGenentech, Inc.

View Study Details

NCT04900818Recruiting

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors....

Dallas, PA330 participantsI-Mab Biopharma US Limited

View Study Details

NCT05941507Recruiting

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expa...

Dallas, PA300 participantsLigaChem Biosciences, Inc.

View Study Details

NCT07335497Recruiting

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) ...

Dallas, PA290 participantsCrescent Biopharma, Inc.

View Study Details

NCT05768932Recruiting

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with tislelizumab or pa...

Dallas, PA260 participantsSillaJen, Inc.

View Study Details

NCT06234397Recruiting

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of BH3120, as a single agent and in combination with pembrolizumab, to assess safety, tolerability, MTD, RP2D, PK, and effic...

Dallas, PA245 participantsHanmi Pharmaceutical Company Limited

View Study Details

NCT06251310Recruiting

SW-682 in Advanced Solid Tumors

This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with...

Dallas, PA186 participantsSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

View Study Details

NCT06956690Recruiting

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ENV-501 in Patients With HER3-Expressing Solid Tumors

This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of ENV-501 in patients with advanced-stage, relapsed...

Dallas, PA180 participantsEndeavor Biomedicines, Inc.

View Study Details

NCT06108050Recruiting

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combin...

Dallas, PA177 participantsJazz Pharmaceuticals

View Study Details

NCT06885281Recruiting

A Study of ZL-1310 in Participants With Selected Solid Tumors

A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors...

Dallas, PA166 participantsZai Lab (Shanghai) Co., Ltd.

View Study Details

NCT07612189Recruiting

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion po...

Dallas, PA155 participantsNEOK Bio, Inc.

View Study Details

NCT07612176Recruiting

A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion p...

Dallas, PA155 participantsNEOK Bio, Inc.

View Study Details

NCT07436728Recruiting

A Study of TAK-505 in Adults With Solid Tumors

Solid tumors occur when cells in an organ or tissue (for example in the lung or liver) start growing out of control (cancer) and form a lump or mass of cells. These solid cancers may grow very far in ...

Dallas, PA151 participantsTakeda

View Study Details

NCT07030257Recruiting

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: ...

Dallas, PA150 participantsTasca Therapeutics

View Study Details

NCT06781983Recruiting

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanc...

Dallas, PA145 participantsInnate Pharma

View Study Details

NCT07605962Recruiting

Phase 1/2 Study of UI-102 in Selected Advanced Cancers

This phase 1/2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle....

Dallas, PA140 participantsUnited Immunity, co., Ltd.

View Study Details

NCT06974110Recruiting

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clini...

Dallas, PA132 participantsMOMA Therapeutics

View Study Details

NCT05394103Recruiting

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monother...

Dallas, PA130 participantsQurient Co., Ltd.

View Study Details

NCT06028074Recruiting

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clini...

Dallas, PA111 participantsGeorgiamune Inc

View Study Details

NCT07148128Recruiting

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours....

Dallas, PA110 participantsAuricula Biosciences Inc.

View Study Details

NCT05490472Recruiting

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors....

Dallas, PA102 participantsJacobio Pharmaceuticals Co., Ltd.

View Study Details

NCT06266299Recruiting

A Study of KK2269 in Adult Participants With Solid Tumors

This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors...

Dallas, PA101 participantsKyowa Kirin Co., Ltd.

View Study Details

NCT06399757Recruiting

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus o...

Dallas, PA100 participantsApollo Therapeutics Ltd

View Study Details

NCT06136884Recruiting

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases

The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies....

Dallas, PA86 participantsA2A Pharmaceuticals Inc.

View Study Details

NCT06234098Recruiting

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-196...

Dallas, PA85 participantsAlyssum Therapeutics

View Study Details

NCT06833008Recruiting

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours. The participants in this study will have...

Dallas, PA85 participantsIpsen

View Study Details

NCT05244551Recruiting

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors

This is an open-label phase 1 study with expansion. The study will start with a dose escalation of single-agent ABSK061 administered in repeated 28-day cycles in patients with advanced solid tumors to...

Dallas, PA85 participantsAbbisko Therapeutics Co, Ltd

View Study Details

NCT05861895Recruiting

HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors

HF158K1 is an investigational liposome form of doxorubicin hydrochloride, an anthracycline topoisomerase inhibitor, encapsulated by lipid membranes containing TL01, a HER2-directed Trastuzumab Fab fra...

Dallas, PA84 participantsHighField Biopharmaceuticals Corporation

View Study Details

NCT05892718Recruiting

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what ...

Dallas, PA80 participantsFBD Biologics Limited

View Study Details

NCT05725291Recruiting

AMT-116 in Patients With Advanced Solid Tumors

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immuno...

Dallas, PA80 participantsMultitude Therapeutics Inc.

View Study Details

NCT06297525Recruiting

Study of STP938 (Dencatistat) in Advanced Solid Tumours

The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy. The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy....

Dallas, PA70 participantsStep Pharma, SAS

View Study Details

NCT05329103Recruiting

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced sol...

Dallas, PA65 participantsPeel Therapeutics Inc

View Study Details

NCT05269316Recruiting

Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors...

Dallas, PA61 participantsImpact Therapeutics, Inc.

View Study Details

NCT06010342Recruiting

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions...

Dallas, PA60 participantsTeligene US

View Study Details

NCT06444815Recruiting

A Study of VET3-TGI in Patients With Solid Tumors

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET...

Dallas, PA60 participantsKaliVir Immunotherapeutics

View Study Details

NCT06600789Recruiting

A Modular Phase 1/2 Study with CT7439 in Participants with Solid Malignancies

This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in partici...

Dallas, PA50 participantsCarrick Therapeutics Limited

View Study Details

NCT04196257Recruiting

BP1001-A in Patients With Advanced or Recurrent Solid Tumors

This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or ma...

Dallas, PA50 participantsBio-Path Holdings, Inc.

View Study Details

NCT06187402Recruiting

A Study of LM-24C5 For Advanced Solid Tumors

To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors....

Dallas, PA49 participantsLaNova Medicines Limited

View Study Details

NCT06750185Recruiting

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

This is a first-in-human (FIH), open-label, multiple-site, dose escalation study which will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 i...

Dallas, PA39 participantsBioNTech SE

View Study Details

NCT07337525Recruiting

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

The goal of this clinical trial is to learn about what doses of PLT012 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of PLT012...

Dallas, PA36 participantsPilatus Biosciences Inc

View Study Details

NCT04370587Recruiting

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced o...

Dallas, PA30 participantsImmVira Pharma Co. Ltd

View Study Details

NCT06415487Recruiting

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expre...

Dallas, PA30 participantsAcepodia Biotech, Inc.

View Study Details

About Advanced Solid Tumors Clinical Trials in Dallas

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 45 advanced solid tumors clinical trials recruiting participants in Dallas, PA. These studies are seeking a combined 16,307 participants. Research is being sponsored by University of Texas Southwestern Medical Center, CStone Pharmaceuticals, Gilead Sciences and 41 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Dallas — FAQ

Are there advanced solid tumors clinical trials in Dallas?

Yes, there are 45 advanced solid tumors clinical trials currently recruiting in Dallas, PA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Dallas?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Dallas research site will contact you about next steps.

Are clinical trials in Dallas free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Dallas studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 45 active trials in Dallas are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated July 13, 2026 from ClinicalTrials.gov